BACKGROUND: We conducted secondary data analyses of a clinical trial (HIVNET 024) to assess risk factors for late postnatal transmission (LPT) of human immunodeficiency virus type 1 (HIV-1) through breast-feeding. METHODS: Data regarding live born, singleton infants of HIV-1-infected mothers were analyzed. The timing of HIV-1 transmission through 12 months after birth was defined as: in utero (positive HIV-1 RNA results at birth), perinatal/early postnatal (negative results at birth, positive at 4-6 week visit), or LPT (negative results through the 4-6 week visit, but positive assays thereafter through the 12-month visit). HIV-1-uninfected infants were those with negative HIV-1 enzyme immunoassay results at 12 months of age, or infants with negative HIV-1 RNA results throughout follow-up. RESULTS: Of 2292 HIV-1-infected enrolled women, 2052 mother/infant pairs met inclusion criteria. Of 1979 infants with HIV-1 tests, 404 were HIV-1-infected, and 382 had known timing of infection (LPT represented 22% of transmissions). Further analyses of LPT included infants who were breast-feeding at the 4-6 week visit (with negative HIV-1 results at that visit) revealed 6.9% of 1317 infants acquired HIV-1 infection through LPT by 12 months of age. More advanced maternal HIV-1 disease at enrollment (lower CD4 counts, higher plasma viral loads) were the factors associated with LPT in adjusted analyses. CONCLUSIONS: In this breast-feeding population, 6.9% of infants uninfected at 6 weeks of age acquired HIV-1 infection by 12 months. Making interventions to decrease the risk of LPT of HIV-1 available and continuing research regarding the mechanisms of LPT (so as to develop improved interventions to reduce such transmission) remain essential.
RCT Entities:
BACKGROUND: We conducted secondary data analyses of a clinical trial (HIVNET 024) to assess risk factors for late postnatal transmission (LPT) of human immunodeficiency virus type 1 (HIV-1) through breast-feeding. METHODS: Data regarding live born, singleton infants of HIV-1-infected mothers were analyzed. The timing of HIV-1 transmission through 12 months after birth was defined as: in utero (positive HIV-1 RNA results at birth), perinatal/early postnatal (negative results at birth, positive at 4-6 week visit), or LPT (negative results through the 4-6 week visit, but positive assays thereafter through the 12-month visit). HIV-1-uninfectedinfants were those with negative HIV-1 enzyme immunoassay results at 12 months of age, or infants with negative HIV-1 RNA results throughout follow-up. RESULTS: Of 2292 HIV-1-infected enrolled women, 2052 mother/infant pairs met inclusion criteria. Of 1979 infants with HIV-1 tests, 404 were HIV-1-infected, and 382 had known timing of infection (LPT represented 22% of transmissions). Further analyses of LPT included infants who were breast-feeding at the 4-6 week visit (with negative HIV-1 results at that visit) revealed 6.9% of 1317 infants acquired HIV-1 infection through LPT by 12 months of age. More advanced maternal HIV-1 disease at enrollment (lower CD4 counts, higher plasma viral loads) were the factors associated with LPT in adjusted analyses. CONCLUSIONS: In this breast-feeding population, 6.9% of infants uninfected at 6 weeks of age acquired HIV-1 infection by 12 months. Making interventions to decrease the risk of LPT of HIV-1 available and continuing research regarding the mechanisms of LPT (so as to develop improved interventions to reduce such transmission) remain essential.
Authors: R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa Journal: J Clin Microbiol Date: 1990-03 Impact factor: 5.948
Authors: S H Landesman; L A Kalish; D N Burns; H Minkoff; H E Fox; C Zorrilla; P Garcia; M G Fowler; L Mofenson; R Tuomala Journal: N Engl J Med Date: 1996-06-20 Impact factor: 91.245
Authors: Barbra A Richardson; Grace C John-Stewart; James P Hughes; Ruth Nduati; Dorothy Mbori-Ngacha; Julie Overbaugh; Joan K Kreiss Journal: J Infect Dis Date: 2003-02-12 Impact factor: 5.226
Authors: Anna Coutsoudis; Francois Dabis; Wafaie Fawzi; Philippe Gaillard; Geert Haverkamp; D Robert Harris; J Brooks Jackson; Valerie Leroy; Nicolas Meda; Philippe Msellati; Marie-Louise Newell; Ruth Nsuati; Jennifer S Read; Stefan Wiktor Journal: J Infect Dis Date: 2004-05-26 Impact factor: 5.226
Authors: Taha E Taha; Donald R Hoover; Newton I Kumwenda; Susan A Fiscus; George Kafulafula; Chiwawa Nkhoma; Shu Chen; Estelle Piwowar; Robin L Broadhead; J Brooks Jackson; Paolo G Miotti Journal: J Infect Dis Date: 2007-05-24 Impact factor: 5.226
Authors: Valériane Leroy; John M Karon; Ahmadou Alioum; Ehounou R Ekpini; Philippe van de Perre; Alan E Greenberg; Philippe Msellati; Michael Hudgens; François Dabis; Stefan Z Wiktor Journal: AIDS Date: 2003-07-04 Impact factor: 4.177
Authors: Lígia M D de Lemos; Joseph Lippi; George W Rutherford; Gabriella S Duarte; Nágyla G R Martins; Victor S Santos; Ricardo Q Gurgel Journal: Int J Infect Dis Date: 2013-06-19 Impact factor: 3.623
Authors: Ying Q Chen; Alicia Young; Elizabeth R Brown; Charles S Chasela; Susan A Fiscus; Irving F Hoffman; Megan Valentine; Lynda Emel; Taha E Taha; Robert L Goldenberg; Jennifer S Read Journal: J Acquir Immune Defic Syndr Date: 2010-07 Impact factor: 3.731
Authors: Elizabeth Brown; Benjamin H Chi; Jennifer S Read; Taha E Taha; Usha Sharma; Irving F Hoffman; Cheryl Pikora; Robert Goldenberg; Susan A Fiscus Journal: AIDS Date: 2008-11-12 Impact factor: 4.177
Authors: Jennifer S Read; Anthony Mwatha; Barbra Richardson; Megan Valentine; Lynda Emel; Karim Manji; Irving Hoffman; Usha Sharma; Robert L Goldenberg; Taha E Taha Journal: J Acquir Immune Defic Syndr Date: 2009-07-01 Impact factor: 3.731